Carbapenem-resistant Gram-negative bloodstream infections in critically ill children: outcome and risk factors in a tertiary teaching hospital in South America

Alvares, P; Arnoni, Mariana Volpe; Silva, C B da; Sáfadi, Marco Aurélio Palazzi; Mimica, Marcelo Jenne

doi:10.1016/j.jhin.2018.10.001

Cited by 4 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding previous antimicrobial exposure, in a recent comparative study performed in children, only carbapenem exposure was significantly associated with CRO infections in the multivariate analysis (41). Other studies in the pediatric population have also observed that prior use of carbapenems was a risk factor for CRO infection (25,31,33,(43)(44)(45). However, the relation to the use of noncarbapenem antibiotics was less clear (33,42,43).…”

Section: Risk Factors For Infection or Colonizationmentioning

confidence: 96%

“…In most cases, patients suffer from underlying comorbid conditions or were admitted to a PICU or NICU (16,37,40). Specific risk factors for colonization or infection with CRO in children include previous antibiotic exposure (mainly to broad-spectrum antibiotics and for an extended duration), the use of medical devices (mostly mechanical ventilation), an ICU stay, prior surgery, and prolonged hospitalization (18,25,31,33,(41)(42)(43)(44)(45) (Table 3).…”

Section: Risk Factors For Infection or Colonizationmentioning

confidence: 99%

See 1 more Smart Citation

Carbapenem-Resistant Gram-Negative Bacterial Infections in Children

Aguilera‐Alonso

Escosa-García

Saavedra-Lozano

et al. 2020

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Carbapenem-resistant organisms (CRO) are a major global public health threat. Enterobacterales hydrolyze almost all β-lactams through carbapenemase production. Infections caused by CRO are challenging to treat due to the limited number of antimicrobial options. This leads to significant morbidity and mortality. Over the last few years, several new antibiotics effective against CRO have been approved. Some of them (e.g., plazomicin or imipenem-cilastatin-relebactam) are currently approved for use only by adults; others (e.g., ceftazidime-avibactam) have recently been approved for use by children. Recommendations for antibiotic therapy of CRO infections in pediatric patients are based on evidence mainly from adult studies. The availability of pediatric pharmacokinetic and safety data is the cornerstone to broaden the use of proposed agents in adults to the pediatric population. This article provides a comprehensive review of the current knowledge regarding infections caused by CRO with a focus on children, which includes epidemiology, risk factors, outcomes, and antimicrobial therapy management, with particular attention being given to new antibiotics.

show abstract

Section: Risk Factors For Infection or Colonizationmentioning

confidence: 96%

Section: Risk Factors For Infection or Colonizationmentioning

confidence: 99%

Carbapenem-Resistant Gram-Negative Bacterial Infections in Children

Aguilera‐Alonso

Escosa-García

Saavedra-Lozano

et al. 2020

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…This poses an emerging threat to global health due to the limited treatment options, elevated mortality rates, high hospitalization costs, and increased challenges in nosocomial infection prevention and control [ 1 ]. In children, carbapenem-resistant gram-negative bacilli infections are primarily associated with healthcare and mainly affect critically ill children, particularly those in pediatric intensive care units (PICUs) [ 2 ].…”

Section: Introductionmentioning

confidence: 99%